The University of Chicago Header Logo

Connection

Hedy Kindler to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Aged, 80 and over.
Hedy Kindler
Connection Strength
2.027
Aged, 80 and over
  1. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.086
  2. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1.
    View in: PubMed
    Score: 0.084
  3. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
    View in: PubMed
    Score: 0.078
  4. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
    View in: PubMed
    Score: 0.048
  5. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71.
    View in: PubMed
    Score: 0.048
  6. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
    View in: PubMed
    Score: 0.048
  7. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
    View in: PubMed
    Score: 0.046
  8. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.044
  9. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar; 12(3):256-62.
    View in: PubMed
    Score: 0.044
  10. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys. 2011 Jan; 38(1):238-44.
    View in: PubMed
    Score: 0.043
  11. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer. 2010 Dec; 9(5):290-6.
    View in: PubMed
    Score: 0.043
  12. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
    View in: PubMed
    Score: 0.042
  13. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
    View in: PubMed
    Score: 0.042
  14. The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2010 Dec; 28(6):854-8.
    View in: PubMed
    Score: 0.039
  15. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6.
    View in: PubMed
    Score: 0.037
  16. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8.
    View in: PubMed
    Score: 0.031
  17. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.030
  18. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93.
    View in: PubMed
    Score: 0.030
  19. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct; 16(10):1639-45.
    View in: PubMed
    Score: 0.030
  20. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004 Dec; 27(6):565-9.
    View in: PubMed
    Score: 0.028
  21. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.
    View in: PubMed
    Score: 0.028
  22. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma. J Thorac Oncol. 2024 Aug; 19(8):1242-1252.
    View in: PubMed
    Score: 0.027
  23. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
    View in: PubMed
    Score: 0.026
  24. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920.
    View in: PubMed
    Score: 0.023
  25. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.022
  26. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621.
    View in: PubMed
    Score: 0.022
  27. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.022
  28. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar; 31(2-3):311-7.
    View in: PubMed
    Score: 0.022
  29. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021 02; 34(2):380-395.
    View in: PubMed
    Score: 0.021
  30. The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1692-1695.
    View in: PubMed
    Score: 0.021
  31. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
    View in: PubMed
    Score: 0.020
  32. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388.
    View in: PubMed
    Score: 0.020
  33. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.020
  34. Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
    View in: PubMed
    Score: 0.020
  35. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
    View in: PubMed
    Score: 0.020
  36. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467.
    View in: PubMed
    Score: 0.019
  37. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013.
    View in: PubMed
    Score: 0.019
  38. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798.
    View in: PubMed
    Score: 0.019
  39. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
    View in: PubMed
    Score: 0.019
  40. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988.
    View in: PubMed
    Score: 0.019
  41. Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332.
    View in: PubMed
    Score: 0.019
  42. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871.
    View in: PubMed
    Score: 0.018
  43. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
    View in: PubMed
    Score: 0.018
  44. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688.
    View in: PubMed
    Score: 0.018
  45. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045.
    View in: PubMed
    Score: 0.018
  46. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. 2018 07; 9(4):367-372.
    View in: PubMed
    Score: 0.018
  47. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
    View in: PubMed
    Score: 0.017
  48. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
    View in: PubMed
    Score: 0.017
  49. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966.
    View in: PubMed
    Score: 0.016
  50. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7.
    View in: PubMed
    Score: 0.015
  51. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74.
    View in: PubMed
    Score: 0.015
  52. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
    View in: PubMed
    Score: 0.015
  53. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80.
    View in: PubMed
    Score: 0.015
  54. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
    View in: PubMed
    Score: 0.014
  55. Radiologic-pathologic correlation of mesothelioma tumor volume. Lung Cancer. 2015 Mar; 87(3):278-82.
    View in: PubMed
    Score: 0.014
  56. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6.
    View in: PubMed
    Score: 0.014
  57. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.014
  58. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
    View in: PubMed
    Score: 0.014
  59. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
    View in: PubMed
    Score: 0.014
  60. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34.
    View in: PubMed
    Score: 0.014
  61. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
    View in: PubMed
    Score: 0.014
  62. The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc. 2013 Nov; 61(11):2043-4.
    View in: PubMed
    Score: 0.013
  63. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.
    View in: PubMed
    Score: 0.013
  64. Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. Med Phys. 2013 Aug; 40(8):081916.
    View in: PubMed
    Score: 0.013
  65. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86.
    View in: PubMed
    Score: 0.013
  66. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
    View in: PubMed
    Score: 0.012
  67. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34.
    View in: PubMed
    Score: 0.012
  68. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
    View in: PubMed
    Score: 0.012
  69. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res. 2013 Jun; 22(5):1105-12.
    View in: PubMed
    Score: 0.012
  70. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
    View in: PubMed
    Score: 0.012
  71. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.012
  72. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
    View in: PubMed
    Score: 0.012
  73. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8.
    View in: PubMed
    Score: 0.011
  74. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
    View in: PubMed
    Score: 0.011
  75. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
    View in: PubMed
    Score: 0.010
  76. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.009
  77. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
    View in: PubMed
    Score: 0.009
  78. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
    View in: PubMed
    Score: 0.009
  79. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
    View in: PubMed
    Score: 0.009
  80. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7.
    View in: PubMed
    Score: 0.009
  81. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007 Oct 10; 25(29):4557-61.
    View in: PubMed
    Score: 0.009
  82. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006 Apr; 186(4):1000-6.
    View in: PubMed
    Score: 0.008
  83. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
    View in: PubMed
    Score: 0.008
  84. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9.
    View in: PubMed
    Score: 0.008
  85. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006 Mar; 92(3):357-60.
    View in: PubMed
    Score: 0.007
  86. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.007
  87. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.
    View in: PubMed
    Score: 0.007
  88. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
    View in: PubMed
    Score: 0.007
  89. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
    View in: PubMed
    Score: 0.007
  90. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.007
  91. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.007
  92. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32.
    View in: PubMed
    Score: 0.007
  93. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May; 44(2):251-9.
    View in: PubMed
    Score: 0.007
  94. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15.
    View in: PubMed
    Score: 0.007
  95. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 2003 Aug; 14(8):1270-3.
    View in: PubMed
    Score: 0.006
  96. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
    View in: PubMed
    Score: 0.006
  97. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
    View in: PubMed
    Score: 0.006
  98. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.006
  99. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000 Sep; 11(9):1161-4.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.